Molecular alterations in ductal carcinoma in situ of the breast

Current Opinion in Oncology

Volumn 14, Issue 1, 2002, Pages 92-96

  Polyak, Kornelia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER MORTALITY; CARCINOGENESIS; CARCINOMA IN SITU; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION; HUMANS;

EID: 0036149044     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200201000-00016     Document Type: Review

References (38)

1. Multistep carcinogenesis of breast cancer and tumor heterogeneity
2. Ductal carcinoma in situ of the breast
3. The fourth EORTC DCIS Consensus meeting (Chateau Marquette, Heemskerk, The Netherlands, 23-24 January 1998)-conference report
4. Pathology of preinvasive and excellent-prognosis breast cancer
5. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast?
6. p53 mutations and expression in breast carcinoma in situ
7. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast
8. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology
9. Clinical implications of the p53 tumor-suppressor gene
10. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction
11. Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: Relation to morphology, cell proliferation and expression of breast cancer-related genes
12. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis
13. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer
14. Heterogeneous chromosomal aberrations in intraductal breast lesions adjacent to invasive carcinoma
15. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by CGH
16. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences
17. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis
18. Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: A new approach for the molecular analysis of paraffin-embedded cancer tissue
19. Laser capture microdissection
20. Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primer
21. Degenerate oligonucleotide-primed PCR (DOP-PCR): Evaluation of its reliability for screening of genetic alterations in neoplasia
22. Serial analysis of gene expression
23. Accessing genetic information with high-density DNA arrays
24. Expression profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide arrays
25. Genes expressed in human tumor endothelium
26. A SAGE (serial analysis of gene expr) view of breast tumor progression
27. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
28. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer
29. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer
30. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells
31. Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk
32. Detection of breast cancer cells in ductal lavage fluid by methylation- specific PCR
33. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine
34. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
35. Loss of cyclin D2 expression in most breast cancers is associated with promoter hypermethylation
36. Pilot studies on the p53 gene in nipple aspirate fluid from patients with breast cancer
37. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions